Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial

Abstract Background It is known that only 50% of patients diagnosed with major depressive disorders (MDD) respond to the first-line antidepressant treatment. Accordingly, there is a need to improve response rates to reduce healthcare costs and patient suffering. One approach to increase rates of tre...

Full description

Bibliographic Details

Published in:	Trials
Main Authors:	Céline K. Stäuble, Markus L. Lampert, Samuel Allemann, Martin Hatzinger, Kurt E. Hersberger, Henriette E. Meyer zu Schwabedissen, Christian Imboden, Thorsten Mikoteit
Format:	Article
Language:	English
Published:	BMC 2021-12-01
Subjects:	Pharmacogenomics Depression Antidepressant Pharmaceutical care Psychiatry
Online Access:	https://doi.org/10.1186/s13063-021-05724-5